Neoadjuvant androgen suppression and external beam radiation therapy.
Zietman
Anthony L
AL
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass., USA. azietman@partners.org
Smith
Christina T
CT
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects / Q000528:radiation effects; D001918:Brachytherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000532:radiotherapy / Q000601:surgery; D051379:Mice; D020360:Neoadjuvant Therapy; D018365:Neoplasm, Residual; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000528:radiation effects; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013739:Testosterone; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013739:Testosterone